Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.19.
Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.
Analysts polled by FactSet expected $44.1 million.
Chief Executive Officer Denny Lanfear said the company expects
cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its "significant" debt and royalty obligations.
"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026," Lanfear said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。